Aeterna Zentaris Revenue and Competitors

Summerville, SC USA

Location

$82.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aeterna Zentaris's estimated annual revenue is currently $1.7M per year.(i)
  • Aeterna Zentaris's estimated revenue per employee is $41,463
  • Aeterna Zentaris's total funding is $82.4M.

Employee Data

  • Aeterna Zentaris has 41 Employees.(i)
  • Aeterna Zentaris grew their employee count by 0% last year.

Aeterna Zentaris's People

NameTitleEmail/Phone
1
Director CommunicationsReveal Email/Phone
2
Coordonnatrice - relations avec les investisseursReveal Email/Phone
3
Chair, Board DirectorsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M390%N/AN/A
#2
$1.7M410%$82.4MN/A
#3
$102.7M5111%N/AN/A
#4
$7M356%N/AN/A
#5
$12.3M61-12%N/AN/A
#6
$410.8M2044-7%N/AN/A
#7
$48.6M2427%N/AN/A
#8
$14.7M730%N/AN/A
#9
$9M45-12%N/AN/A
#10
$10.7M534%N/AN/A
Add Company

What Is Aeterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

keywords:N/A

$82.4M

Total Funding

41

Number of Employees

$1.7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aeterna Zentaris News

2022-04-19 - Aeterna Zentaris Secures New European Patent Related to ...

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and...

2022-04-13 - Aeterna Zentaris Abstract Accepted for Presentation at 13th ...

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and...

2022-03-30 - Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 ...

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A4114%N/A
#2
$8.2M428%N/A
#3
$11M438%N/A
#4
$8M445%N/A
#5
N/A45150%N/A